Mostrando 5 resultados de: 5
Filtros aplicados
Publisher
Current Drug Targets(2)
European Journal of Clinical Pharmacology(1)
Pharmacogenomics(1)
Therapeutic Drug Monitoring(1)
Área temáticas
Farmacología y terapéutica(5)
Enfermedades(3)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Origen
scopus(5)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusPharmacogenetics of clinical response to risperidone
ReviewAbstract: Despite risperidones proven safety and efficacy, existing pharmacogenetic knowledge could be appliedPalabras claves:Biomarkers, Clinical outcome, pharmacogenetics, Risperidone, side effectsAutores:Adrián LLerena, Berecz R., Humberto Fariñas, Penãs-Lledó E.M., Süveges A.Fuentes:scopusUse of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
ArticleAbstract: Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. TwoPalabras claves:CYP2D6, High-pressure liquid chromatography, pharmacogenetics, Therapeutic drug monitoring (TDM), ThioridazineAutores:Adrián LLerena, Benitez Rodriguez J., Berecz R., De la Rubia A., Norberto M.Fuentes:scopusThe role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
ReviewAbstract: In the recent years it has been increasingly recognized that pharmacogenetical factors play an imporPalabras claves:CYP2D6, CYP3A4, metabolism, pharmacogenetics, RisperidoneAutores:Adrián LLerena, Berecz R., Cáceres M.C., De la Rubia A., Degrell I., Dorado P.Fuentes:scopusThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
ArticleAbstract: Background: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450Palabras claves:Cytochrome p450, pharmacogenetics, smoking, ThioridazineAutores:Adrián LLerena, Berecz R., Dahl M.L., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopus